ReShape Lifesciences (OTCMKTS:RSLS) Vs. PAVmed (NASDAQ:PAVM) Financial Comparison
ReShape Lifesciences (OTCMKTS:RSLS) Vs. PAVmed (NASDAQ:PAVM) Financial Comparison
ReShape Lifesciences (OTCMKTS:RSLS – Get Rating) and PAVmed (NASDAQ:PAVM – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
重塑生命科學(OTCMKTS：RSLS-GET Rating)和PAVmed(納斯達克：PAVM-GET Rating)都是小盤醫療公司，但哪隻股票更優？我們將根據兩家公司的分析師建議、盈利能力、收益、估值、股息、機構所有權和風險等方面的強弱對它們進行比較。
Valuation & Earnings
估值與收益
This table compares ReShape Lifesciences and PAVmed's revenue, earnings per share (EPS) and valuation.
此表比較了Rehape Lifesciences和PAVmed的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ReShape Lifesciences | $13.60 million | 0.17 | -$61.93 million | ($197.50) | -0.02 |
| PAVmed | $500,000.00 | 95.77 | -$50.35 million | ($0.98) | -0.50 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 重塑生命科學 | 1,360萬美元 | 0.17 | -6,193萬元 | ($197.50) | -0.02 |
| PAVmed | $500,000.00 | 95.77 | -5,035萬元 | ($0.98) | -0.50 |
PAVmed has lower revenue, but higher earnings than ReShape Lifesciences. PAVmed is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks.
與重塑生命科學相比，PAVmed的收入較低，但收益較高。PAVmed的市盈率低於重塑生命科學，這表明它目前是兩隻股票中更負擔得起的一隻。
Profitability
盈利能力
This table compares ReShape Lifesciences and PAVmed's net margins, return on equity and return on assets.
此表比較了Rehape Lifesciences和PAVmed的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| ReShape Lifesciences | -577.18% | -72.89% | -58.52% |
| PAVmed | N/A | -112.81% | -70.55% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 重塑生命科學 | -577.18% | -72.89% | -58.52% |
| PAVmed | 不適用 | -112.81% | -70.55% |
Volatility & Risk
波動性與風險
ReShape Lifesciences has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.
Rehape Lifesciences的貝塔係數為0.02，這意味着其股價的波動性比標準普爾500指數低98%。相比之下，PAVmed的貝塔係數為0.88，這意味着其股價的波動性比標準普爾500指數低12%。
Analyst Recommendations
分析師建議
This is a summary of current ratings and recommmendations for ReShape Lifesciences and PAVmed, as provided by MarketBeat.
這是MarketBeat提供的對重塑生命科學和PAVmed的當前評級和建議的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ReShape Lifesciences | 0 | 0 | 1 | 0 | 3.00 |
| PAVmed | 0 | 1 | 1 | 0 | 2.50 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 重塑生命科學 | 0 | 0 | 1 | 0 | 3.00 |
| PAVmed | 0 | 1 | 1 | 0 | 2.50 |
ReShape Lifesciences presently has a consensus price target of $2.88, suggesting a potential downside of 35.68%. PAVmed has a consensus price target of $3.56, suggesting a potential upside of 627.04%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than ReShape Lifesciences.
重塑生命科學公司目前的一致目標價為2.88美元，這意味着潛在的下跌幅度為35.68%。PAVmed的普遍目標價為3.56美元，暗示潛在上漲627.04%。考慮到PAVmed更有可能的上行空間，分析師們顯然認為，PAVmed比重塑生命科學更有利。
Institutional and Insider Ownership
機構和內部人持股
3.3% of ReShape Lifesciences shares are held by institutional investors. Comparatively, 14.0% of PAVmed shares are held by institutional investors. 1.6% of ReShape Lifesciences shares are held by company insiders. Comparatively, 13.2% of PAVmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
重塑生命科學3.3%的股份由機構投資者持有。相比之下，機構投資者持有PAVmed股份的比例為14.0%。重塑生命科學1.6%的股份由公司內部人士持有。相比之下，PAVmed 13.2%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一隻股票有望實現長期增長。
Summary
摘要
PAVmed beats ReShape Lifesciences on 8 of the 13 factors compared between the two stocks.
在比較兩隻股票的13個因素中，有8個方面，PAVmed勝過重塑生活科學。
About ReShape Lifesciences
關於重塑生命科學
(Get Rating)
(獲取評級)
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. The company was founded in December 2002 and is headquartered in San Clemente, CA.
重塑生命科學公司是一家醫療設備公司，專注於治療肥胖和代謝性疾病的技術。其產品組合包括Lap-Band可調胃束帶系統、重塑市場、Obalon氣球系統、重塑背心和糖尿病塊狀神經調節設備。該公司成立於2002年12月，總部設在加利福尼亞州聖克萊門特。
About PAVmed
關於PAVmed
(Get Rating)
(獲取評級)
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.
PAVmed，Inc.是一家商業階段的技術醫療器械公司，致力於醫療技術的商業化。它通過以下部門運作：醫療設備、診斷、數字健康和新興創新。其產品包括細胞採集設備、食道DNA測試、腕管釋放、植入性骨內血管接入設備和抗菌可吸收耳管。該公司成立於2014年6月26日，總部設在紐約州紐約。
Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受重塑《生命科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收關於重塑生命科學和相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。